Grove Bank & Trust’s AbbVie ABBV Stock Holding History

Grove Bank & Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.86M	Sell	15,353 -71	-0.5%	-$15.3K	0.38%	53
2026 Q1	$3.35M	Buy	15,424 +515	+3%	+$114K	0.38%	53
2025 Q4	$3.41M	Buy	14,909 +71	+0.5%	+$16.2K	0.38%	54
2025 Q3	$3.44M	Sell	14,838 -122	-0.8%	-$24.8K	0.4%	56
2025 Q2	$2.78M	Sell	14,960 -77	-0.5%	-$14.3K	0.35%	62
2025 Q1	$3.15M	Buy	15,037 +1,896	+14%	+$369K	0.42%	53
2024 Q4	$2.34M	Buy	13,141 +282	+2%	+$51.8K	0.32%	62
2024 Q3	$2.54M	Buy	12,859 +149	+1%	+$27.8K	0.38%	56
2024 Q2	$2.18M	Sell	12,710 -149	-1%	-$24.7K	0.35%	55
2024 Q1	$2.34M	Sell	12,859 -3,863	-23%	-$666K	0.39%	51
2023 Q4	$2.59M	Buy	16,722 +246	+1%	+$35.9K	0.48%	46
2023 Q3	$2.46M	Buy	16,476 +735	+5%	+$108K	0.5%	46
2023 Q2	$2.12M	Sell	15,741 -976	-6%	-$143K	0.43%	49
2023 Q1	$2.66M	Buy	16,717 +259	+2%	+$39.6K	0.56%	34
2022 Q4	$2.66M	Sell	16,458 -3,223	-16%	-$494K	0.59%	34
2022 Q3	$2.64M	Sell	19,681 -1,678	-8%	-$241K	0.65%	32
2022 Q2	$3.27M	Sell	21,359 -1,195	-5%	-$183K	0.78%	28
2022 Q1	$3.66M	Buy	22,554 +894	+4%	+$130K	0.72%	31
2021 Q4	$2.93M	Sell	21,660 -83	-0.4%	-$9.8K	0.56%	40
2021 Q3	$2.35M	Buy	21,743 +181	+0.8%	+$20.7K	0.49%	45
2021 Q2	$2.43M	Buy	21,562 +780	+4%	+$87.8K	0.53%	42
2021 Q1	$2.25M	Buy	20,782 +9	+0%	+$963	0.53%	42
2020 Q4	$2.23M	Buy	20,773 +1,161	+6%	+$112K	0.58%	41
2020 Q3	$1.72M	Sell	19,612 -2,180	-10%	-$205K	0.53%	46
2020 Q2	$2.14M	Buy	21,792 +2,195	+11%	+$193K	0.7%	33
2020 Q1	$1.49M	Buy	19,597 +856	+5%	+$72.9K	0.59%	43
2019 Q4	$1.66M	Buy	18,741 +181	+1%	+$15K	0.5%	48
2019 Q3	$1.41M	Buy	18,560 +1,293	+7%	+$88.6K	0.45%	53
2019 Q2	$1.26M	Buy	17,267 +1,280	+8%	+$101K	0.46%	58
2019 Q1	$1.29M	Buy	15,987 +1,256	+9%	+$103K	0.49%	52
2018 Q4	$1.36M	Sell	14,731 -2,694	-15%	-$237K	0.63%	40
2018 Q3	$1.65M	Sell	17,425 -688	-4%	-$65.2K	0.68%	35
2018 Q2	$1.68M	Sell	18,113 -766	-4%	-$74.8K	0.72%	35
2018 Q1	$1.79M	Sell	18,879 -67	-0.4%	-$7.36K	0.79%	31
2017 Q4	$1.83M	Sell	18,946 -257	-1%	-$24.2K	0.8%	27
2017 Q3	$1.71M	Buy	19,203 +3,081	+19%	+$235K	0.83%	26
2017 Q2	$1.17M	Buy	16,122 +2,052	+15%	+$138K	0.75%	29
2017 Q1	$917K	Sell	14,070 -2,647	-16%	-$166K	0.75%	32
2016 Q4	$1.05M	Buy	16,717 +1,506	+10%	+$91.9K	0.8%	33
2016 Q3	$959K	Buy	15,211 +1,520	+11%	+$98.4K	0.82%	35
2016 Q2	$848K	Buy	13,691 +1,396	+11%	+$85.1K	0.76%	37
2016 Q1	$702K	Buy	12,295 +2,062	+20%	+$115K	0.64%	44
2015 Q4	$606K	Buy	+10,233	New	+$589K	0.54%	47

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grove Bank & Trust's ABBV Position: Q2 2026 in Review

Grove Bank & Trust reduced its AbbVie (ABBV) stake by 0.46% in Q2 2026, selling an estimated $15.3K and leaving 15,353 shares worth $3.86M. The position accounts for 0.38% of the portfolio, ranked #53.

Grove Bank & Trust first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Grove Bank & Trust held 15,353 shares of AbbVie worth $3.86M as of Q2 2026.
Grove Bank & Trust sold 71 AbbVie shares in Q2 2026, an estimated $15.3K.
AbbVie made up 0.38% of Grove Bank & Trust's portfolio in Q2 2026, its #53 holding.
Grove Bank & Trust first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.